HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HRID 575334Erstellt: 24. Oktober 2026
(R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol → HCID 178422861, Verbindung
https://huagongshe.com/de/reaction/575334
Beteiligte Stoffe
| Rolle | Name | HCID | Einwaage |
|---|
| Edukt | (R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol | HCID 86669593 | — |
| Edukt | HCID 178422860 | HCID 178422860 | — |
| Produkt | HCID 178422861 | HCID 178422861 | — |
Reaktionsschritte
10-bromo-9-fluoro-3-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with (2-tert-butoxycarbonyl-5-methyl-pyrazol-3-yl)boronic acid similarly to as described in Example 4 to produce crude 10-bromo-9-fluoro-3-(3-methyl-1H-pyrazol-5-yl)-5,6dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide. 10-bromo-9-fluoro-3-(3-methyl-1H-pyrazol-5-yl)-5,6dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with (2R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol via General Procedure E to afford 5.8 mg (6.6%) 9-fluoro-10-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-ynyl]-3-(3-methyl-1H-pyrazol-5-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2-carboxamide following reverse phase purification. M+1=478.
Herkunft & Nachweise
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patentnummer | US09034866B2 |
|---|
| Quelldatensatz | uspto-grants-2015_05 |
|---|
| ORD ID | ord-218afa56868b4151b112229c7f1bfec6 |
|---|
| Quellennotiz | uspto-grants-2015_05 |
|---|